Genetics of amyotrophic lateral sclerosis: an update

Sheng Chen1,2, Pavani Sayana2, Xiaojie Zhang1 and Weidong Le1*

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder involving both upper motor neurons (UMN) and lower motor neurons (LMN). Enormous research has been done in the past few decades in unveiling the genetics of ALS, successfully identifying at least fifteen candidate genes associated with familial and sporadic ALS. Numerous studies attempting to define the pathogenesis of ALS have identified several plausible determinants and molecular pathways leading to motor neuron degeneration, which include oxidative stress, glutamate excitotoxicity, apoptosis, abnormal neurofilament function, protein misfolding and subsequent aggregation, impairment of RNA processing, defects in axonal transport, changes in endosomal trafficking, increased inflammation, and mitochondrial dysfunction. This review is to update the recent discoveries in genetics of ALS, which may provide insight information to help us better understanding of the disease neuropathogenesis.

Keywords: Amyotrophic lateral sclerosis, Disease-related gene mutations, Autophagy, Apoptosis, Oxidative stress, Glutamate excitotoxicity

Background

Amyotrophic lateral sclerosis (ALS) is a heterogeneous group of neurodegenerative disorders characterized by progressive loss of motor neurons of the primary motor cortex, brainstem and spinal cord, consequently resulting in muscle weakness, paralysis and ultimately the death [1]. Patients present with either limb onset (80% cases) or bulbar onset (20% cases). In limb onset cases, symptoms appear either distally or proximally in either the upper or lower limb. Bulbar onset cases usually manifest with dysarthria and dysphagia, and limb symptoms can develop along with bulbar symptoms or may occur in the due course of the disease within a year [1]. Most ALS patients come across both upper motor neuron (UMN) and low motor neuron (LMN) signs. The typical age onset is about 55 years [2]. It progresses at a fast pace with most of the patients dying within 3–5 years of the onset [2]. However there is also a small subset of ALS cases that present with a relatively slower disease course. The incidence of the disease is approximately similar worldwide ranging from 1 to 2 new cases per 100,000 individuals every year and the prevalence is around 4–6 cases per 100,000 individuals [2].

ALS has no definitive diagnostic test and it is diagnosed clinically in most cases. There is no cure for ALS, although the only FDA approved drug Riluzole may increase certain ALS patient survival by 3 months [3]. Considerable progress has been made in comprehending the genetics of ALS in the past decade. Interestingly, recent studies have demonstrated that ALS may be a multisystem neurodegenerative disease in which brain and brain stem are also affected [1-3]. For example, several cases suffered from ALS exhibit symptoms of cognitive impairment, which is pathologically characterized by cytoplasmic ubiquitin-positive inclusions in hippocampus and neocortical neurons in addition to anterior horn neurons [1-3]. In this review, we summarize the genetic breakthroughs in familial ALS (fALS) and sporadic ALS (sALS) and depict how it shapes our understanding of disease pathogenesis and our quest for rational therapies.

Genetics of ALS

ALS can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. 90% ALS are sporadic cases with no clear genetic linkage. However, the remaining 10% of cases show familial inheritance [4,5].
In the last few years, there has been a rapid advance in our knowledge of genetic causes for ALS. Furthermore, the relationship between the genetic subtypes and the pathological subtypes as well as clinical phenotype has become more and more clear. In addition to superoxide dismutase 1 (SOD1), mutations in the genes coding for TAR DNA-Binding Protein (TARDBP), fused in sarcoma (FUS), Ubiquilin2 (UBQLN2), C9ORF72 and several others are closely associated with typical clinical phenotype. Figure 1 provides up-to-date findings of genetic defects in ALS and the underlying mechanisms for the cause and pathogenesis of the disease.

**Genetics of fALS**

The causative genes have been identified in almost 5-10% of all fALS cases to date [4,5]. Among those 20% of fALS cases are caused by the mutation in SOD1 gene, 4-5% of fALS cases are the results of mutations in TARDBP and FUS genes, more than 30% of fALS cases are associated with C9ORF72 mutations and the rest are

![Figure 1](http://www.molecularneurodegeneration.com/content/8/1/28)

**Figure 1** ALS is caused by interplay of various molecular pathways in motor neurons and an interaction with neighbouring non-neuronal cells like microglia and astrocytes. Microglial cells activate an inflammatory cascade via secretion of cytokines. Astrocytes lead to motor neuron injury through release of inflammatory mediators such as nitric oxide and prostaglandin E2. Accumulation of superoxide radicals and oxidative stress, aberrant RNA processing, protein misfolding and insoluble proteins may cause motor neuron degeneration in ALS. Protein aggregation may lead to endoplasmic reticulum stress along with defective endosomal trafficking and mitochondrial damage, which may cause organelle disruption and activates autophagy and apoptotic pathways. Axonal transport abnormalities lead to energy deficiency in the axon along with the defective axonal growth and axonal dysfunction. Axonal dysfunction, defective angiogenesis and metabolic disturbance may contribute to motor neuron degeneration in ALS.
due to the mutations in alsin, senataxin (SETX), spatacsin, vesicle associated membrane protein associated protein B (VAPB), angiogenin (ANG), factor induced gene 4 (FIG 4), optineurin (OPTN) and perhaps other unknown genes [see Table 1].

**ALS1/ superoxide dismutase 1 (SOD1)**

SOD1 is the first gene to be identified in fALS based on linkage analysis in autosomal dominant fALS pedigrees, which maps to chromosome 21q22.1 [5]. Individuals with mutant SOD1 present mostly with limb onset, starting predominantly in lower limb rather than upper limb. A few cases also present with bulbar onset. To date more than 150 mutations have been found in all 5 exons affecting the functional domains of SOD1 predominantly in missense mutations, although a small percentage of nonsense mutations, insertions and deletions have also been reported. Mutations in SOD1 have been reported in ~20% of fALS and in ~1-4% of sALS [2]. SOD1 mutant ALS cases show ample variation in the phenotype in the age of onset, severity, rate of disease progression and duration. SOD1 genotype analysis illustrates variable clinical phenotypes, indicating that the phenotype is modified by genetic as well as environmental factors [4].

The SOD1D90A mutation which is recessive in a Scandinavian population is shown to be related with autosomal dominant ALS in other genetic groups [2]. Patients carrying the SOD1A4V mutations have shorter survival with

### Table 1 The genetics Of fALS

| Genetic subtype | Chromosomal locus | Gene | Protein | Onset | Inheritance | Clinical feature | Other diseases caused by the gene |
|-----------------|-------------------|------|---------|-------|-------------|-----------------|-----------------------------------|
| ALS1            | 21q22.1           | SOD1 | Cu/Zn SOD-1 | Adult | AD/AR       | Typical ALS     | NA                                |
| ALS2            | 2q33-2q35         | Alsin| Alsin    | Juv   | AR          | Slowly progressive, predominantly UMN signs like limb, & facial spasticity | PLS IAHP |
| ALS3            | 18q11            | Unknown| Unknown | Adu   | AD          | Typical ALS with limb onset especially lower limb | NA |
| ALS4            | 9q34             | SETX | Senataxin | Juv   | AD          | Slowly progressive, distal hereditary motor neuropathy with pyramidal signs | SCAR 1 and AOA2 |
| ALS5            | 15q15-21         | SPTG1| Spataxin | Juv   | AR          | Slowly progressive | HSP |
| ALS6            | 16p11.2          | FUS | Fused in Sarcoma | Juv/Adu | AD/AR | Typical ALS | NA |
| ALS7            | 20q13.3          | VAPB | VAPB    | Adu   | AD          | Typical and atypical ALS | SMA |
| ALS9            | 14q11.2          | ANG | Angiogenin | Adu   | AD          | Typical ALS | NA |
| ALS10           | 1p36.2           | TARDBP| DNA-binding protein | Adu | AD | Typical ALS | NA |
| ALS11           | 6q21             | FIG 4| Phosphoinositide-Sphosphatasease | Adu | AD | Rapid progressive with prominent corticospinal tract signs | CMT 4 J |
| ALS12           | 10p13            | OPTN | Optineurin | Adu   | AD/AR | Slowly progressive with limb onset and predominant UMN signs | Primary Open Angle Glaucoma |
| ALS14           | 9p13.3           | VCP | VCP     | Adu   | AD          | Adult onset, with or without FTD | IBMFPD |
| ALS15/ ALSX     | Xp11             | UBLQ2 | Ubiquilin 2 | Adu/Juv | XD | UMN signs proceeding L MN signs | NA |
| ALS16           | 9p13.2-21.3      | SIGMAR1| SIGMAR1 | Juv   | AR          | Juvenile onset typical ALS | FTD |
| ALS-FTD1        | 9q21-22          | unknown| unknown | Adu   | AD          | ALS with FTD | FTD |
| ALS-FTD2        | 9p21             | C9ORF72| C9ORF72 | Adu   | AD          | ALS with FTD | FTD |
| NA              | 2p13             | DCTN1| Dynactin | Adu   | AD          | Distal hereditary motor neuropathy with vocal paresis | NA |

Other rare-occurring ALS genes

| Genetic subtype | Chromosomal locus | Gene | Protein | Onset | Inheritance | Clinical feature | Other diseases caused by the gene |
|-----------------|-------------------|------|---------|-------|-------------|-----------------|-----------------------------------|
| ALS3            | 18q21             | Unknown| Unknown | Adu   | AD          | Typical ALS with limb onset especially lower limb | NA |
| ALS7            | 20qter-p13        | Unknown| Unknown | Adu   | AD/AR       | Typical ALS | NA |
| NA              | 12q22-23          | DAO  | DAO     | Adu   | AD          | Typical ALS | NA |

Up to date, more than 20 ALS genes have been identified in fALS. These genetic mutations represent different molecular pathways of motor neuron degeneration. Abbreviations for Table 1: PLS Primary Lateral Sclerosis, IAHP Infantile onset ascending hereditary spastic paralysis, SCAR 1 Autosomal Recessive Spino-cerebellar ataxia, AOA2 Ataxia Ocular Apraxia 2, HSP Hereditary spastic paraplegia, VAPB Vesicle associated membrane protein associated protein B, SMA Spinal Muscular Atrophy, CMT 4 J Charcot-Marie Tooth disease type 4 J, VCP Valosin Containing Protein, IBMFPD Inclusion body myopathy with Pagets disease and fronto temporal dementia, SIGMAR1 Sigma Non Opiod Intracellular Receptor, C9ORF72 Chromosome 9 open reading frame 72, PD Parkinson disease, DAO D-Amino Acid Oxidase, FTD Frontal-temporal dementia, AD Autosomal dominant, AR Autosomal recessive.
death occurring in less than one and half year after the diagnosis, and the penetrance of the gene mutation is 91% [2]. The SOD1A89V mutation has incomplete penetrance, variable age at onset and sensory neuropathy [6]. The SOD1I113T mutation is highly diverse in the age of onset, clinical manifestations, disease progression and penetrance [7,8].

SOD1 is a cytoplasmic protein, which is a homodimer of 153 amino acids, containing one copper and one zinc atom [2,5]. Copper plays a role in SOD1 activity, whereas zinc is contributed to structural stability. SOD1 detoxifies superoxide radicals, a by-product of oxidative phosphorylation, to hydrogen peroxide and oxygen, which are converted to water and oxygen by catalase and glutathione peroxidase enzymes [2,5]. The exact mechanism by which SOD1 mutations lead to ALS pathology is unknown although numerous hypotheses have been proposed to explain SOD1-mediated toxicity such as misfolding proteins-associated aggregation, oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, glutamate excitotoxicity, inflammation and microglial activation and axonal transport abnormalities [2,5]. Several mutant SOD1 transgenic mice have been generated and SOD1G93A mice are the mostly used model for ALS studies [9]. This mouse model has been successfully used in variety of studies to define the molecular mechanism of the disease and evaluate new drug responses [9]. Interestingly, SOD1 knockout mice do not develop ALS, although they do exhibit some age-dependent distal motor neuropathy compared with SOD1G93A mice, which supports the notion that toxic gain of function may be responsible for the motor neuron degeneration in SOD1G93A mice since enzymatic activity is retained in SOD1G93A mutation [10].

ALS2/ALSIN

ALS2 is a rare, autosomal recessive, juvenile onset (mean age at onset is 6.5 years) disease characterized by limb and facial spasticity, spastic dysarthria, uncontrolled laughter, subsequent lower motor neuron signs and bladder dysfunction [2,11]. The locus of ALS2 is mapped to chromosome 2q33-2q35 via linkage analysis in a large Tunisian kindred [2,11]. The deletion mutations result in frame shifts that result in a premature stop codon. Alsin is alternatively spliced to produce a long and a short transcript. Deletion mutations in the short transcript cause ALS2 and those in the long transcript lead to juvenile primary lateral sclerosis (PLS) [11]. Alsin is a Rab5 and Rac1 guanine nucleotide exchange factor (GEF) domain promoters. It promotes neurite outgrowth in cell cultures through activation of the small GTPase Rac1 macropinocytosis-associated endolysosomal trafficking via the fusion between endosomes and autophagosomes [11]. Alsin protects cultured motor neurons from mutant SOD1 toxicity suggesting its neuroprotective role [12]. Overexpression of alsin inhibits mutant SOD1G93A-induced endosomal Rac1 activation and reactive oxygen species production [13,14]. The mutations in alsin may induce a loss of this neuroprotective function by disrupting the endolysosomal system and causing an aggregation of immature vesicles and misfolded proteins in neurons [13,14]. Alsin knock-out mice models demonstrate that the loss of alsin can result in motor neuron damage, but no definitive features consistent with ALS or other motor neuron disease. However, not all the studies support that alsin knock-out mice might develop motor neuron degeneration. Cai et al. and Gros-Louis et al. reported that alsin knock-out mice displayed signs of corticospinal track degeneration but did not develop obvious progressive motor neuron degeneration [15,16]. These mice have increased vulnerability to oxidative stress, indicating that alsin variants might be a risk factor rather than directly cause of motor neuron degeneration [15,16].

ALS4/senataxin (SETX)

ALS4 is a rare, juvenile onset, autosomal dominant ALS, characterized by distal limb weakness, muscle atrophy, and pyramidal signs [1,2,17]. Bulbar and respiratory muscles are spared. Disease progression is slow and the patients usually have a normal life span [1,2,17]. ALS4 is linked to chromosome 9q34 [17] and sequencing 19 genes in this locus reveals 3 distinct missense mutations in the SETX gene in 3 families with ALS [18]. In addition, positional cloning technique reveals that the mutations in SETX gene in the locus also associated with autosomal recessive spinocerebellar ataxia-1 (SCAR1), which is also referred to ataxia-ocular apraxia-2 (AOA2) [19]. SETX gene encodes a ubiquitously expressed DNA/RNA helicase protein [19,20]. SETX and DNA/RNA helicases are involved in DNA repair, replication, recombination, transcription, RNA processing, transcript stability, and the initiation of translation [19,20]. SETX is similar to several genes involved in RNA processing such as the immunoglobulin mu binding protein 2 gene (IGHMBP2), mutations in which are known to cause spinal muscular atrophy with respiratory distress type 1 [20], implying that SETX mutations-caused motor neuron degeneration may result from the aberrant RNA processing [21].

ALS5/spatacsin (SPG)

ALS5 also known as juvenile ALS type 1 is the most common form of recessive fALS with juvenile onset. Most of the cases present before the age of 25 yrs [22,23]. It follows a slow progressive course that can survive more than 3 decades. A study in 22 patients with ALS from 7 families links ALS5 to chromosome 15q15-
21 and mutations in SPG11 gene [22,23]. SPG11 gene mutations cause autosomal recessive hereditary spastic paraplegia (HSP) with atrophied corpus callosum [22,23], and share certain clinical, pathological and genetic features of ALS according to a study in 25 families from Italy, Brazil, Canada, Turkey, and Japan [24]. A total of 12 mutations in SPG11 gene have been identified, out of which 10 are either nonsense mutations or insertions or deletions leading to a frame shift, indicating a loss of function [24]. SPG11 is a protein with four transmembrane domains, a leucine zipper and a coil domain. This protein is identified in central nervous system, especially in the cortical and spinal motor neurons as well as in the retina, showing multiple organelles like protein-trafficking vesicles, endoplasmic reticulum and microtubules, and the accumulation of spatacsin like protein-trafficking vesicles, endoplasmic reticulum rons as well as in the retina, showing multiple organelles in non-myelinated axons suggesting axonal transport disturbance [25].

**ALS6/fused in sarcoma (FUS)**

ALS patients with ALS6 mutations are characterized by a wide range of disease onset from 26–80 years with the mean duration around 33 months [2]. Most cases show LMN predominance, without bulbar region involvement and no cognitive impairment. The locus for ALS6 has been mapped to chromosome 16p11.2 encoding FUS gene [26]. Mutations in FUS gene are identified based on a linkage analysis in a large Cape Verde family with autosomal recessive ALS and in numerous British kindred with autosomal dominant ALS [27]. Up to now, more than 50 FUS mutations have been identified in ~4% cases of fALS and ~1% of sALS cases [27]. FUS mutations are also found in fALS patients with frontal-temporal dementia (FTD) and in juvenile ALS patients with basophilic inclusions [28]. In addition, FUS is the major component of nuclear polyQ aggregates of Huntington disease (HD) as well as spinocerebellar ataxia type 1, 2, 3, and dentatorubral-pallidoluysian atrophy [29]. Histopathological analysis of FUS mutant cases illustrates distinctive FUS positive and TDP-43 negative inclusions and an earlier age of onset is noted in cases with basophilic and compact neuronal cytoplasmic [28]. FUS gene encodes for a DNA/RNA binding protein that has multiple domains and the domain at N-terminus plays a role in transcriptional activation of the gene [30,31]. As a nuclear protein and mutations at the C-terminus disrupt the transport of FUS into the nucleus, which lead to cytoplasmic localization of FUS and formation of stress granules [30,31]. Overexpression of mutant FUS in a transgenic mouse model develops progressive paralysis due to motor axonal degeneration and neuronal loss in the cortex and hippocampus [32]. In transgenic Drosophila model, it has been observed age-dependent progressive motor neuron damage when Wt, R524S or P525L mutant FUS are over-expressed in photoreceptors [33]. In addition, over-expressing WT or mutant FUS C. elegant models and knocking down endogenous FUS Zebrafish models are both used to study the mechanism of FUS mediated motor neurodegeneration [27].

**ALS8/ vesicle associated membrane protein associated protein B (VAPB)**

ALS8 is first described in a large Brazilian kindred with 28 affected male and female family members from across 4 generations [34]. Clinical onset occurs between ages 31 and 45 years, and the patients present with postural tremor, fasciculations, slow progressive upper and lower limb weakness [34]. The disease has an unusually long course compared to typical ALS. Linkage analysis reveals a novel locus at chromosome 20q13.3 and the mutation analysis depicts a mutation in the VAPB protein, which replaces the amino acid proline with the amino acid serine at position 56 [34]. A different mutation (T46I) is detected within the same domain of VAPB protein in a UK patient [35]. VAPB is an integral endoplasmic reticulum membrane protein, which has various functions such as the intracellular vesicle trafficking, lipid transport and the unfolded protein response [34,35]. Both the mutations in the VAPB domain lead to VAPB aggregation into immobile ER clusters which causes lower level of VAPB, resulting in a decreased ER anchoring of lipid-binding proteins and motor neuron degeneration [34,35]. The expression of VAPB is significantly decreased in human ALS patients and SOD1-ALS transgenic mice, suggesting that VAPB may be involved in the pathogenesis of sALS and SOD1-linked ALS [36]. A study on mutant VAPB transgenic mice shows TDP-43 cytoplasmic inclusions, implying a link between VAPB mutated and TDP-43 mislocalization [37]. The VAPB mutation alters the binding of VAPB to tyrosine phosphatase-interacting protein 51 (PTPIP51) and increases Ca2+ uptake by mitochondria following the release from ER stores [38]. However, a study from Qiu et al. shows that overexpression of VAPB in mouse spinal cord can produce abundant VAPB aggregates, but it is not associated with motor neuron degeneration, indicating that the mutant VAPB aggregates may cause motor neuron degeneration by loss of function rather than gain-of-toxicity [39].

**ALS9/angiogenin (ANG)**

ALS caused by ANG gene mutation is named as ALS9, an autosomal dominant adult onset disease presenting with the classic signs of ALS. A few patients also presented with parkinsonism and signs of FTD [40]. ANG is located at chromosome 14q11.2 and is first identified in ALS patients from Ireland and Scotland [40]. Seven missense mutations in ANG have been
detected in 15 patients on a screening analysis of a large cohort of Irish, Scottish, English, Swedish and North American ALS cases, out of which 4 are fALS and the rest sALS [40]. ANG mutations are not associated with fALS in Italian population [41]. Few fALS cases are identified to have concomitant ANG mutations with FUS mutations [42] or with SOD1 mutations [43].

The ANG protein belongs to pancreatic ribonuclease superfamily, and it plays a role in inhibiting of protein translation by cleaving tRNA and helps in rRNA biogenesis and cellular proliferation [40,42,43]. ANG mediates neovascularization and promotes neurite outgrowth during early embryonic development [44]. Mutations in ANG gene cause loss of ribonucleolytic activity and nuclear translocation activity [44].

**ALS10/TAR DNA binding protein (TARDBP)**

Mutations of gene TARDBP was first reported in fALS cases in 2008 [45]. Since then, over 40 mutations have been identified in various ethnic groups with an incidence of ~4-5% in fALS and up to 2% in sALS. TARDBP-related ALS patients present as adult-onset, autosomal dominant form of ALS with predominant limb onset and a wide variation in the age of onset (30–77 yrs) and disease duration. TARDBP mutations are observed in both ALS-FTD and FTD cases. Ubiquitinated TARDBP (TDP-43) is one of the major components of cytoplasmic inclusions in ALS and FTD [45]. TDP-43 positive cytoplasmic inclusions are found in many neurodegenerative disorders such as sALS, FTD, HD, Alzheimer’s disease (AD) and PD [46]. TDP-43 is a DNA/RNA binding protein, belonging to ribonucleoprotein family. TDP-43 is involved in a variety of functions in nucleus process, including gene transcription, RNA splicing, microRNA processing and stabilization as well as transport of mRNA [47]. Almost all the TARDBP mutations identified in ALS patients are missense mutations within the glycine-rich C-terminal region, involved in protein-protein interactions. TDP-43 has many binding targets, including FUS, vasolin containing protein (VCP), progranulin, and other transcripts encoding neurodegenerative disease-associated proteins as well as many other RNA processing genes [47]. Furthermore, by using individual-nucleotide resolution UV-cross linking and immunoprecipitation, Tollervey et al. found that TDP-43 can bind to nuclear paraspeckle assembly transcript 1 (NEAT1) and metastasis associated lung adenocarcinoma transcript 1 (MALAT1) non-coding RNAs [48,49]. It can also influence alternative splicing in position-dependent manner to Nova proteins, indicating that TDP-43 may play an essential role in splicing regulation in central nerve system [48,49]. TDP-43 interacts with mutant, but not wild-type SOD1 mRNA, thereby linking the two distinct genetic pathogenic mechanisms [50]. It is not clear how TARDBP mutations cause motor neuron degeneration, due to a loss of nuclear function or a gain of toxic function. Up to date, there are numerous animal models of TDP-43. These models expressing human wild-type or the ALS-linked mutants A315T or M337V TDP-43 (hTDP-43) under the control of the murine prion protein promoter (moPrP) display motor neuron degeneration, indicating gain-of-function mechanism [51,52]. Furthermore, the mice with high-expressing homozygous TAR4/4 display a spastic paralysis of UMN degeneration [51,52]. Up-regulation of TDP-43 in motor neurons may alter RNA metabolism via alternative splicing and RNA stability, which may increase ALS risk [51-54]. Increase of the TDP-43 level is associated with formation of TDP-43 inclusions in the nucleus and mislocalization of SMN–GEMs (Survival Motor Neuron containing Gemini of coiled bodies) and alter RNA metabolism [51,53]. On the other hand, loss of function may also play a role. For example, the lack of TDP-43 in forebrains of mice may lead to age-dependent brain atrophy. It is known that loss of TDP-43 may down-regulate Tbc1d1 protein in skeletal muscle and then induce hypermetabolism which can compromise neuronal function [51,53]. Interestingly, TARDBP knockout mice model shows decreased level of TDP-43 and body weight reduction which may result from increasing fat oxidation and accelerating fat loss in adipocytes [51].

**ALS11/FIG 4**

It is an autosomal dominant adult onset ALS with a rapid progressive course, early bulbar involvement and slight cognitive impairment [2]. Mutations in FIG 4 also known as Sac1 domain containing protein 3 (SAC3) gene located on chromosome 6q21 has been found as a causative gene for ALS11 [2]. In a screening test conducted for FIG 4 mutations in a large North European cohort of fALS and sALS patients, 5 heterozygous mutations, 1 missense, 2 splicing, and 2 truncating mutations have been identified [55].

FIG 4 is a phosphoinositide 5-phosphatase that regulates PI(3,5)P2, a signaling lipid that helps in retrograde trafficking of endosomal vesicles to the trans-Golgi network [56]. Mutations in FIG 4 result in neurodegeneration in sensory and autonomic ganglia, motor cortex, and striatum [55-57]. It is still not certain yet whether mutations of FIG 4 cause neurodegeneration through a dominant negative mechanism or a partial loss of function as in Charcot-Marie Tooth disease type 4 J (CMT4J) [55]. Furthermore, mutant mice with absent Vac14, a gene coding for an FIG 4 interactor, also shows neurodegeneration. Mutations in the two components of the PI(3,5)P2 regulatory complex, FIG 4 and Vac14, lead to cytoplasmic inclusion body formation containing p62,
LC3-II and LAMP-2 in the brain, suggesting that autophagy may play a role in the gene mutations induced neurodegeneration [57].

**ALS12/optineurin (OPTN)**

ALS12 is an adult onset autosomal recessive or autosomal dominant ALS characterized by lower limb onset with UMN involvement and a slow disease progression [2]. It maps to chromosome 10p13, a genetic analysis of this gene reveals a homozygous deletion of exon 5 and another homozygous nonsense (Q398X) mutation [2]. Two homozygous mutations and a heterozygous missense mutation (E478G) are identified in a large cohort of fALS and sALS [4]. OPTN is co-localized with FUS, TDP43 and SOD1 in inclusion bodies of sALS and fALS [4]. In HD cortex, OPTN is seen in neuronal intranuclear inclusions co-labeled with ubiquitin [4]. This protein participates in multitasaking cytosolic protein process involved in protein trafficking, maintenance of the Golgi complex, and exocytosis [4]. ALS12 is inherited in an autosomal recessive manner, and the OPTN protein causes neurotoxicity through the loss of function mechanism [4,5,58,59]. However, in heterozygous mutations with autosomal dominant inheritance, dominant negative effect may play a role [4,5,58,59]. Nuclear factor-κB (NF-κB), which is activated by tumor necrosis factor-alpha can be regulated by OPTN and mutations in the gene can lead to uninterrupted NF-κB neurotoxicity [4]. OPTN can be phosphorylated by protein kinase TANK binding kinase 1 (TANK1) and then promote selective autophagy function of ubiquitin-coated substance [59]. Furthermore, Koraj et al. found that OPTN can activate autophagy-lysosome pathway and clearance of protein aggregation via ubiquitin-independent manner [60]. These two studies highlight that OPTN is an important factor in autophagy process.

**ALS14/ valosin containing protein (VCP)**

ALS 14 is an adult onset autosomal dominant inherited motor neuropathy with an average disease onset of 49 yrs [2]. The clinical character includes limb-onset motor neuron symptoms with rapidly progress [2]. In an Italian family with autosomal dominant ALS patients, using exome sequencing technique, a single heterozygous missense mutation in the gene coding for VCP is located on chromosome 9p13.3 [61]. Additional screening conducted on the VCP gene in 210 fALS cases and 78 autopsy-proven ALS cases has identified 3 more VCP mutations in 4 patients [61]. VCP mutations are a rare cause of fALS and clinical features could include FTD, Paget's disease, inclusion body myopathy, and parkinsonism.

VCP is a hexameric type II ATPase of the AAA family involved in multiple cellular functions, including protein homeostasis through endoplasmic reticulum-associated degradation (ERAD), Golgi biogenesis, assembly of peroxisomes, vesicle transport and fusion and autophagy [2,61]. VCP plays a role in ER stress by activating the unfolded protein response (UPR) that leads to aggregation of misfolded proteins and causes apoptotic cell death [2,61]. VCP also plays a major role in ubiquitin-dependent protein degradation [62]. Quantitative immunohistochemical study of VCP in the skin from patients with ALS and controls reveals that the proportion of VCP-positive cells in the epidermis in ALS is higher than that in controls and this proportion is higher in ALS patients with longer duration of illness [63].

**ALS15/ALSX/ubiquilin 2 (UBQLN2)**

ALSX is an adult or juvenile onset, X-linked dominantly inherited disease [2]. Patients present with UMN and LMN involvement, and UMN signs typically precede LMN signs [2]. A few of them even have dementia. UBQLN2 gene maps to chromosome Xp11. Linkage analysis in a 5 generation kindred with 19 affected candidates reveals a distinct point mutation in the coding region of UBQLN2 gene which substituted proline with histidine [64]. Later on 4 more missense mutations are identified in 4 unrelated families, all substituting proline with some other amino acid [65]. UBQLN2 is a member of the ubiquitin like protein family, which regulates the ubiquitin proteasome system (UPS) of protein degradation by delivering ubiquitinated proteins to proteasome [64-66]. Mutations in UBQLN2 impairs protein degradation pathway which can lead to an abnormal protein aggregation and neurodegeneration. UBQLN2 inclusions can be seen in the spinal cord in patients with UBQLN2 mutations [64-66]. These inclusions are also positive for other ALS proteins such as Ubiquitin, p62, TDP-43, FUS and OPTN, but negative for SOD1 [64-66]. UBQLN2 inclusions are also found in fALS, sALS and ALS-dementia cases without UBQLN2 mutations [66].

**ALS16/SIGMAR1**

ALS16 is reported in a Saudi Arabian family [67]. Patients show UMN signs of spasticity and hyperreflexia in the initial years of life, develop LMN signs later, and progress to paralysis [67]. By homozygosity mapping, a linkage is found on chromosome 9p13.2-21.3, and using candidate gene sequencing, a mutation is identified in SIGMAR1 (SIGMA Non Opiod Intracellular Receptor1) gene [67]. Linkage studies done in 2 pedigrees, a Dutch and a Scandinavian family established a connection between familial ALS with FTD to chromosome 9p13.2-21.3 [68]. In the Scandinavian family, ALS and FTD occur separately; however, in Dutch family all the members show both ALS and FTD symptoms [67-69]. Mutation screening in 34 genes on chromosome 9p using linkage analysis in a multi-generation kindred with
ALS + FTD has identified a nucleotide substitution in the 3'UTR of the SIGMAR1 gene [69]. The SIGMAR1 protein functions as a subunit of the ligand regulated potassium channel, which can bind to neurosteroids, psychostimulants, and dextrobenzomorphans [69]. The 3'UTR alterations of the SIGMAR1 are hypothesized to alter the stability of the transcript and dysregulate the channel activity [69].

**ALS-FTD1 and ALS-FTD2**

ALS-FTD1 is an adult onset, autosomal dominant disorder which presents with the symptoms of both fALS and FTD [2,58]. ALS-FTD1 is linked to chromosome 9q21-q22 in a linkage analysis conducted on 16 ALS-FTD pedigrees [70].

Patients with ALS-FTD2 present with an adult onset, autosomal dominant fALS and FTD [2,71]. Linkage of ALS-FTD2 to chromosome 9p21 has been reported and a hexanucleotide GGGGCC repeat expansions in the chromosome 9 open reading frame 72 (C9ORF72) gene has recently been identified as the causal genetic defect of ALS-FTD2 [71]. C9ORF72 repeat expansions are currently the most frequently genetic cause of fALS and FTD, accounting for approximately 34.2 and 25.9% of the cases, respectively [72]. C9ORF72 ALS has both p62/ubiquitin- and TDP-43 positive inclusions. The loss-of function and gain-of function have been proposed. For clinical phenotype, C9ORF72 mutation manifests FTD and ALS as well as other features including memory loss, psychosis, akinetic-rigid and cerebellar signs [73]. Recent studies indicate that C9ORF72 hexanucleotide repeat could generate insoluble polypeptides specific to C9RANT immunoreactivity by non-ATG (RAN)-initiated translation, which cannot be found in other neurodegenerative diseases such as CAG repeat disorders [74,75]. These findings may provide evidence for better understanding of ALS mechanisms and treatment strategies targeting to non-ATG (RAN)-translated peptides [74-76].

**Dynactin (DCTN1)**

In a study made on large kindred with a slow progressive autosomal dominant distal hereditary motor neuropathy, a mutation has been identified in the p150 subunit of DCTN1 gene mapped on chromosome 2p13. Later on 3 more mutations have been identified in DCTN1 gene in sALS, FALS and ALS-FTD families [77]. Dynactin is a microtubule motor protein that couples ATP hydrolysis for cellular motility in cilia and flagella [78]. The binding of dynactin to dynein is critical in the axonal transport of vesicles and organelles [78]. Thus DCTN1 mutations are thought to cause neurodegeneration by impairing axonal transport in motor neurons. Additionally, G59S missense mutation in microtubule-binding domain of p150glued, a major component of dynein/dynactin complex can cause motor neuron degeneration [79]. In G59S p150glued knock-in mice, MND-like phenotypes appear after 10 months old. Loss of spinal motor neurons, increase of reactive astrogliosis and excessive accumulation of cytoskeleton and synaptic vesicle proteins at the neuromuscular junctions are observed [79]. The motor neuron degeneration is also observed in mutant human dynactin p150glued overexpression mice model [80]. These results indicated the role of dynactin in ALS pathogenesis [80,81].

**Other rare occurring mutant genes in fALS**

Using whole genome linkage analysis with microsatellite markers in a set of families with proven ALS cases, a missense mutation in the D-amino acid oxidase (DAO) gene located on chromosome 12q22-23 has been reported in a single three generation pedigree [82]. The patients with the mutation show classical ALS signs with a rapid progression and an early bulbar involvement with a limited decline in cognitive skills [82]. DAO gene encodes a peroxisomal flavin adenine dinucleotide (FAD)-dependent oxidase that is seen in neurons and glial cells of brainstem and spinal cord [83]. R199W mutations in DAO decrease the cell viability, increase the formation of ubiquitinated aggregates and enhance the apoptosis in primary motor neuron cultures [82,83]. When motor neurons are cultured alongside the astrocytes expressing R199W mutation, similar features are documented, indicating that motor neuron death induced by this mutation can be mediated by both cell autonomous and non-cell autonomous processes [82]. However it is still not clear if the neurodegenerative effect is from the accumulation of the aberrant proteins or from an impaired enzyme activity [83,84]. Impaired enzyme activity leads to the buildup of D-amino acids like D-serine, an agonist at the glycine site of the N-methyl-DL-aspartic acid (NMDA) receptor, enhancing glutamate transmission and may exacerbate motor neuron death [84]. D-serine is increased both in ALS patients and in SOD1G93A mouse model of ALS [84].

ALS3 has been mapped to chromosome 18q21 in a large European family [2]. This locus consists of almost 50 genes and the exact gene causing the disease is not yet to be identified. In one of the pedigrees, a genetic subtype of ALS, designated ALS7, is linked to chromosome 20pter-p13 [2]. The ALS patients in the family show the signs of adult onset fALS with rapid disease progression [2].

**Genetics of sALS**

The incidence of sALS is more in men than in women [1,2]. The only clinical feature that distinguishes recognized sporadic from apparently hereditary ALS is older...
age of onset in the former [1-3]. All the clinical features reported in hereditary cases including the extrapyramidal and cerebellar signs or cognitive involvement have also been observed in sALS [1-3]. The cause of sALS in most cases is not known. Several fALS genes such as C9ORF72, TDP-43, FUS and SOD1 have also been reported in a small proportion of sALS cases [5]. The crosslink between genetic and environmental factors may contribute to the pathogenesis of sALS [1-4]; Table 2. Discovering causative mechanisms in sALS will facilitate effective treatments and cures for this disease.

**Apurinic endonuclease (APEX1)**

Mutation analysis conducted on 117 Scottish sALS patients shows a SNP association ending in a D148E amino-acid change in APEX1 [85]. However, later on two other studies fail to confirm this finding [86]. This might imply that APEX1 mutations may cause sALS in a particular geographic population. APEX1 participates in the process of DNA repair and DNA binding of transcription factors and plays a protective role against oxidative stress [87]. APEX1 is a unique redox factor, but the mutants will lose redox activity and fail to stimulate cell proliferation. APEX1’s redox function is also shown to be neuroprotective after exposure to ionizing radiation which produces reactive oxygen species and oxidative DNA damage in neurons [87].

**Charged multivesicular body protein 2B (CHMP2B)**

A splice site mutation of CHMP2B is first revealed in a Danish family as a rare cause of FTD accounting for <1% of the total cases [88]. Patients present with predominant LMN phenotype and one of the patients even shows signs of FTD [88,89]. Later on CHMP2B gene sequencing in 433 ALS patients from England has identified three missense mutations in fALS and sALS cases [88]. CHMP2B belongs to CHMP family and the protein is components of ESCRT-III, a complex involved in degradation of surface receptor proteins and in the trafficking of proteins between plasma membrane, trans-golgi network and lysosomes [88,89]. CHMP2B mutations in FTD cases can result in disrupted endosomal structure which is similar to those seen in alsin mutations [88,89]. In addition, CHMP2B mutations lead to dendritic retraction and autophagosomal aggregation in cortical neurons and in hippocampal neurons, implying that CHMP2B is needed for dendritic spine growth and maturation [90,91].

**Neurofilaments**

Neurofilaments are neuronal cytoplasmic intermediate filaments that form the cytoskeleton of myelinated axons. Neurofilaments are formed by the subunits of different molecular masses light (NEFL), medium (NEFM), and heavy (NEFH), which are encoded by different genes [92]. The abnormal accumulation of neurofilaments in the cell bodies and proximal axons of motor neurons is pathognomonic [92]. Association between NEFH and ALS has been shown in a small group of patients [92]. Overexpression of NEFH, NEFL, and peripherin, as well as the decreased activity of the dynein protein can cause paralytic symptoms in mice associated with axonal atrophy and motor dysfunction [93]. NEFL is required for neurofilament assembly; thus, in NEFL null mice, NEFM and NEFH cannot assemble and transport accurately, leading to reduced levels in axons [93]. Mutations in

| Table 2 The genetics Of sALS |
|-----------------------------|
| Gene | Protein | Chromosomal locus | Variant associated with ALS |
| APEX1 | Apurinic Endonuclease DNA repair enzyme 1 | 1q11.2 | SNP associations |
| ATXN2 | Ataxin-2 | 12q24.12 | Poly Q repeats |
| CHMP2B | Chromatin Modifying Protein 2B | 3p11.2 | Mutations |
| HFE | Haemochromatosis | 6p22.2 | SNP associations |
| NEFH | Neuro filament Heavy | 22q12.2 | Deletion and Insertions |
| SMN1 | Survival Motor Neuron 1 | 5q12.2-q13.3 | Abnormal copy number of genes |
| SMN2 | Survival Motor Neuron 2 | 5q12.2-q13.3 | Abnormal copy number of genes |
| PON 1,2,3 | Paraoxonase | 7q21.3 | SNP associations and mutations |
| PRPH | Peripherin | 12q13.12 | mutations |
| VEGF | Vascular Endothelial Growth Factor | 6p21 | Promoter SNP’s |
| PGRN | Progranulin | 17q21.31 | Deletions |

Although the cause of sALS is not known, the crosslink between genetic and environmental factors may contribute to the pathogenesis of sALS. APEX1, ATXN2, CHMP2B, HFE, NEFH, SMN1, SMN2, PON 1, PON2, PON3, PRPH, VEGF and PGRN are some of the genes associated with sALS. Single Nucleotide Polymorphisms (SNP’s), Polyglutamine (Poly Q) repeats, abnormal copy number of genes, deletion and insertion mutations are some of the associations found with the genes known to cause sporadic ALS. Abbreviations for Table 2: APEX1 Apurinic Endonuclease DNA repair enzyme 1, ATXN2 Ataxin-2, CHMP2B Charged multivesicular body protein 2B, HFE Haemochromatosis, NEFH Neuro filament Heavy, SMN Survival Motor Neuron, PON Paraoxonase, PRPH Peripherin, VEGF Vascular Endothelial Growth Factor, PGRN Progranulin.
NEFL are known to cause a form of hereditary sensory and motor neuropathy, Charcot-Marie-Tooth disease [94]. The C-terminal of NEFH contains phosphorylation motifs called lys-ser-pro repeats that have 2 polymorphic variants of short and long repeats. Homozygosity for the short repeat allele is associated with sALS in a study conducted on Russian patients [95]. Deletions and insertions in the C-terminal KSP repeats of NEFH are noted in some sALS patients [92].

**Paraoxonase**

The paraoxonases (PON) have 3 units (PON1, PON2, and PON3) located on 80-kb block of chromosome 7q21.3. PON1 and PON3 are primarily expressed in liver and reach to the blood where they are associated with high-density lipoproteins and may protect against atherosclerosis, whereas PON2 is expressed in many tissues [96]. PON1 and PON2 have been found to express in mouse brain [96,97]. PON proteins are involved in the hydrolysis of lactones and in the detoxification of organophosphate pesticides, neurotoxins and aromatic esters. The PON gene polymorphisms are found to be associated with sALS [98,99]. The haploblock of high linkage disequilibrium spanning PON2 and PON3 is also associated with sALS [98]. Recently a genomic DNA sequencing study has identified seven mutations in the PON genes in patients with fALS and sALS [100]. Furthermore, it has been shown that neurotoxicity caused by oxidative stress in PON2 knockout mice is more significant than in wild type mice, indicating that PON2 might have a neuroprotective effect against oxidative stress [96].

**Peripherin (PRPH)**

PRPH is a type III intermediate filament similar to neurofilaments. It acts as a cytoskeletal protein and is present in the neurons of the peripheral nervous system [101]. PRPH expression is increased in the spinal motor neurons after neuronal injury, indicating its role in axonal regeneration [101]. Lewy body-like ubiquitinated inclusions and Bunina bodies that are seen in some ALS patients contain PRPH [101]. Overexpression of wild-type PRPH in transgenic mice develops a selective, large scale late-onset motor neuron degeneration characterized by intermediate filament inclusions [102]. Later on 2 homozygous missense mutations have been identified in PRPH gene [103]. A study on 122 Italian ALS patients has identified eighteen sequence variations on PRPH including 2 missense variations, namely p.R133P and p.D141Y [103]. These two variants are predicted to have a deleterious effect on protein structure or function [103]. PRPH splice variants are noted in certain mouse models which may contribute to the ALS pathogenesis. A pathogenic isoform of PRPH (Per61) is found in motor neurons of mutant SOD1 mice but not in wild-type transgenic mice [104]. Per61 is not able to assemble properly, but it can form intracellular aggregates and then cause neurotoxicity [104]. Per61 is also observed in the motor neurons from mutant TDP-43 transgenic mice but not from wild-type TDP-43 mice [105]. Recently, another PRPH splice variant (Per28) is found in ALS patients, overexpression of which leads to PRPH aggregation in transgenic mouse model [106].

**Survival motor neuron (SMN) 1 AND 2**

SMN is in a structure named ‘GEMS’ (Gemini of the coiled bodies) which has important function in mRNA metabolism. SMN and its associated protein, SMN-interacting protein-1 (SIP1), form a complex with several spliceosomal snRNP (small nuclear Ribo Nucleo Protein) [107,108]. The impaired assembly and function of the spliceosome could cause motor neuron degeneration. Homozygous deletion mutations of SMN1 gene on chromosome 5 cause the autosomal recessive disorder spinal muscular atrophy (SMA), a fatal childhood-onset neuromuscular disease characterized by the degeneration of spinal cord motor neurons and subsequent muscle paralysis [107]. A study on 110 ALS patients and 100 controls found an increased frequency of SMN2 deletions in sALS patients (16%) in controls (4%), suggesting that SMN2 deletion may be a risk factor for ALS [108]. In another study on 167 ALS patients for SMN1 and SMN2 copy number, 16% ALS patients have an abnormal copy numbers of SMN1 [109]. Although the involved SMN gene is different in the two studies, both suggest that the SMN copy numbers is associated with ALS. Homozygous deletion mutations in SMN genes are not found in ALS but an abnormal copy numbers in SMN1 could increase the risk for ALS [109]. Further studies are needed to clarify the role of the SMN1 and SMN2 genes in sALS.

**Vascular endothelial growth factor (VEGF)**

VEGF plays a role in angiogenesis in response to hypoxia. Deletion of hypoxia-responsive element from the VEGF promoter in mice can cause the late-onset motor neuron degeneration similar to ALS [110]. Two experiments conducted on mutant SOD1 transgenic mice by overexpressing VEGF, one through delivery in muscle and the other through intra-cerebroventricular administration, prolong the survival in mutant SOD1 rats [111]. Spinal cords of ALS patients show reduced expression of VEGF and its receptor [112]. All these lead to the identification of VEGF as a possible candidate gene for ALS. Mutation sequencing of the VEGF gene and VEGF promoter in ALS patients fails to identify any specific mutations. However, a study performed on 750 ALS patients and over 1200 controls from Sweden, Belgium and England reveal that certain SNPs in the VEGF gene are
associated with the lower level of VEGF expression and higher risk of ALS, suggesting a link between VEGF levels and ALS susceptibility [113].

Progranulin (PGRN)

It is a glycoprotein that is a precursor for granulins or epithelins involved in the development, inflammation and wound repair [114]. PGRN has also been linked to tumorigenesis and activated microglia in several neurodegenerative diseases [114]. Nonsense and deletion mutations of PGRN are known to be the cause of ubiquitin positive, tau negative FTD (FTDU) [115]. To date, only a single study links PGRN mutations to ALS [115].

Ataxin-2 (ATXN2)

Ataxin-2, the protein encoded by the ATXN2 gene, contains a polyglutamine (polyQ) tract with normally 22–23 repeats. Intermediate length polyQ repeats (23–34) are found in ALS patients [97]. ATXN2 and TDP-43 form a RNA-dependent complex, and longer polyQ repeats stabilize ATXN2 and increases its interaction with TDP-43. This leads to enhanced dislocation of TDP-43 into the cytoplasm in the spinal cord motor neurons in ALS patients [116]. ATXN2 is also able to interact with endophilins involved in synaptic vesicle endocytosis [117].

Conclusion

There is a great heterogeneity for genetic spectrum of fALS and sALS. Several genes in ALS are known to cause many other neurodegenerative diseases, such as alsin with PLS and infantile onset ascending hereditary spastic paralysis (IAHSP), Senataxin with SCAR1 or AOA2, spatacins with HSP, VAPB with SMA, FIG 4 with CMT type 4 J, OPTN with primary open angle glaucoma. In addition, there is a clinical and pathological overlap between ALS and FTLD. A number of autosomal-dominant genes have been described as primarily cause ALS or FTD such as VCP, and TARDBP. The presence of two neurodegenerative phenotypes within the same family and even within the same individual naturally raises question about the genetic and environmental interaction on the disease initiation.

Using linkage analysis, candidate gene studies and genome wide association studies, about 1/3 fALS and a small number of sALS have been revealed the disease-caused genes. However, despite all the progress achieved, the causes of large majority of sALS remain unknown. With the advanced genetics technology, we can expect that the number of genes involved in fALS as well as sALS will continue to increase. In addition, the utilization of transgenic animal models may provide useful tool to study the pathogenesis of ALS. Emphasis should also be made on elaborating the gene-environment interactions and crosslink in ALS, as 90% of the cases are sporadic in origin, which may help better understand the nature of the disease.

It is difficult to predict the future outcome in ALS research, but the identification of novel genes, gene modifiers and the different molecular pathways caused by the aberrant genes, might advance our research in this area. Hopefully, the use of the deep sequencing techniques, transgenic animal models, retrograde studies on available data and prospective design of future studies, may help broaden our vision in understanding the ALS genetics and pathogenesis. Strategic approach based on new ALS genes and drug trials on animal models should enable us to uncover new treatment modalities.

Abbreviations

AD: Alzheimer’s disease; AD: Autosomal dominant; ALS: Amyotrophic lateral sclerosis; ANG: Angiogenin; AOA2: Ataxia Ocular Apraxia 2; APEX1: Apurinic Endonuclease DNA repair enzyme 1; AR: Autosomal recessive; ATXN2, Ataxin-2; C9ORF72: Chromosome 9 open reading frame 72; CHMP2B: Chromatin Modifying Protein 2B; CMT 4 J: Charcot-Marie Tooth disease type 4 J; DAO: D-Amino Acid Oxidase; DCXN: Dynactin; ESCR-T: endosomal sorting complex required for transport III; FALS: familial ALS; FIG 4: Factor Induced Gene 4; FTD: Frontal-temporal dementia; GEF: Guanine nucleotide exchange factor; HD: Huntington’s disease; HFE: Haemochromatosis; HSP: Hereditary spastic paraplegia; IAHSP: Infantile onset ascending hereditary spastic paralysis; IBM/FPD: Inclusion body myopathy with Pagets disease and frontotemporal dementia; IGIBM2: Immunoglobulin mu binding protein 2 gene; LMN: Lower motor neurons; NEFH: Neuro filament heavy; NF-kB: Nuclear factor-kB; OPTN: Optineurin; PD: Parkinson disease; PGRN: Progranulin; PL: Primary lateral sclerosis; PON: Paraoxonase; PRP: Peripherin; sALS: sporadic ALS; SCAR 1: Autosomal Recessive Spiro-cerebellar ataxia; SETX: Senataxin; SIGMAR1: Sigma Non Opioid Intracellular Receptor; SIP1: SMN-interacting protein-1; SMA: Spinal Muscular Atrophy; SMN1: Survival Motor Neuron 1; SMN2: Survival Motor Neuron 2; SOX1: Superoxide Dismutase 1; SPG: spatacin; UBQLN2: Ubiquilin 2 UMN, upper motor neurons; UPS: Ubiquitin–proteasome system; VAPB: Vesicle associated membrane protein associated protein B; VCP: Valosin containing protein; VEGF: Vascular endothelial growth factor.

Competing interests

The authors declare that they have no competing interests.

Authors’ contribution

SC contributed to update genetic and mechanism of ALS most part of manuscript, make revision and correction. PS contributed to the draft of the paper and figure. XZ contributed to the revision of the paper. All the authors have read and approved the final manuscript.

Acknowledgement

This paper is funded by China National Nature Science Foundation (No 81200977, 81000541 and 81171201).

Author details

1Institute of Neurology, Jiao Tong University School of Medicine, 1201 Room, 11 Building, Ruijin Er Road, Shanghai 200025, China. 2Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.

Received: 8 April 2013 Accepted: 29 July 2013
Published: 13 August 2013

References

1. Appel SH, Zhao W, Beers DR, Henkel JS: The microglial-motoneuron dialogue in ALS. Acta Neurol scand 2011, 130:4–8.

2. Pasinelli P, Brown RH: Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 2006, 7:10–723.

3. Czapinski A, Yen AA, Simpson EP, Appel SH: Slower disease progression and prolonged survival in contemporary patients with amyotrophic...
lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing? Arch Neurol 2006, 63:1139–1143.

4. Maruyama H, Morino H, Ito H, Uzumi Y, Kato H, Watanabe Y, Kinosita Y, Kamada M, Nodaer H, Suzuki H, Komure O, Matsuura S, Kobakate K, Morimoto N, Abe K, Suzuki N, Aski M, Kawata A, Hirai T, Kato T, Ogawaara K, Hirano A, Takumis T, Kusaka H, Hayagawa K, Kaji R, Watanabe H: Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 462:223–226.

5. Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, Ince PG, Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kwong LK, Forman MS, Ravits J, Stewart H, Eisen A, McClusky L, Kretzschmar HA, Picker W, Martin E, Ouvrard-Hernandez AM, Teisa A, Bouslam N, Losass A, Charles P, Loueille JL, Elleuche N, Conflaveux C, Cruz VT, Rubio M, Leguern E, Gird D, Taniz M, Fontaine B, Filla A, Berti L, Arru A, Brice A: Mutations in SPG11, encoding spastin, are a major cause of spinocerebellar ataxia with typical corpus callosum. Nat Genet 2007, 39:366–372.

6. Grohmann K, Schuelke M, Diers A, Hoffmann K, Lucke B, Adams C, Bentini E, Lehnardt-Horti H, Muntoni F, Ouvrard-Hernandez AM, Teisa A, Bouslam N, Losass A, Charles P, Loueille JL, Elleuche N, Conflaveux C, Cruz VT, Rubio M, Leguern E, Gird D, Taniz M, Fontaine B, Filla A, Berti L, Arru A, Brice A: Mutations in SPG11, encoding spastin, are a major cause of spinocerebellar ataxia with typical corpus callosum. Nat Genet 2007, 39:366–372.

7. Hadano S, Ikeda JE: ALS2/alsin deficiency in neurons leads to mild defects through RhoGEF domain by interacting with SOD1 mutants. J Biol Chem 2007, 282:33551–33560.

8. Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kow LK, Forman MS, Ravits J, Stewart H, Eisen A, McClusky L, Kretzschmar HA, Picker W, Martin E, Ouvrard-Hernandez AM, Teisa A, Bouslam N, Losass A, Charles P, Loueille JL, Elleuche N, Conflaveux C, Cruz VT, Rubio M, Leguern E, Gird D, Taniz M, Fontaine B, Filla A, Berti L, Arru A, Brice A: Mutations in SPG11, encoding spastin, are a major cause of spinocerebellar ataxia with typical corpus callosum. Nat Genet 2007, 39:366–372.

9. Chou T, Ishikawa K, Ushio Y, Takeyasu A, Sakakibara K, Hattori T, Ito H, Suzuki N, Aoki M, Kawata A, Hirai T, Kato T, Ogasawara K, Morimoto N, Abe K, Suzuki N, Aski M, Kawata A, Hirai T, Kato T, Ogawaara K, Hirano A, Takumis T, Kusaka H, Hayagawa K, Kaji R, Watanabe H: Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 462:223–226.

10. Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, Ince PG, Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kwong LK, Forman MS, Ravits J, Stewart H, Eisen A, McClusky L, Kretzschmar HA, Picker W, Martin E, Ouvrard-Hernandez AM, Teisa A, Bouslam N, Losass A, Charles P, Loueille JL, Elleuche N, Conflaveux C, Cruz VT, Rubio M, Leguern E, Gird D, Taniz M, Fontaine B, Filla A, Berti L, Arru A, Brice A: Mutations in SPG11, encoding spastin, are a major cause of spinocerebellar ataxia with typical corpus callosum. Nat Genet 2007, 39:366–372.

11. Otomo A, Kunita R, Suzuki-Utsunomiya K, Mizumura H, Onoe K, Osuga H: Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nat Genet 2001, 29:175–79.

12. Kanekura K, Hashimoto Y, Niikura T, Aiso S, Matsuoka M, Nishimoto I: ALS2/alsin deficiency in neurons leads to mild defects through RhoGEF domain by interacting with SOD1 mutants. J Biol Chem 2007, 282:33551–33560.

13. Li Q, Spencer NY, Pantazis NJ, Engelhardt JF: Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nat Genet 2001, 29:175–79.

14. Otomo A, Kunita R, Suzuki-Utsunomiya K, Mizumura H, Onoe K, Osuga H: Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nat Genet 2001, 29:175–79.
37. Tudor EL, Galtrey CM, Perkinton MS, Lau KF, De Vo KJ, Mitchell JC, Ackerley S, Hortobágyi T, Vámos E, Leigh PN, Klassen C, McLoughlin DM, Shaw CE, Miller CC. Amyotrophic lateral sclerosis mutant vesicle-associated membrane protein-associated protein-B transgenic mice develop TAR-DNA-binding protein-43 pathology. Neuroscience 2010, 167:74–78.

38. De Vo KJ, Mórtz GM, Soica R, Tudor EL, Lau KF, Ackerley S, Harry A, Shaw CE. Miller CC. CPB1 interacts with the mitochondrial protein PTTP51 to regulate calcium homeostasis. Hum Mol Genet 2012, 21:1299–1311.

39. Qiu L, Qiao T, Beers M, Tan W, Wang H, Yang B, Xu Z. Widespread aggregation of mutant VAPB associated with ALS does not cause motor neuron degeneration or modulate mutant SOD1 aggregation and toxicity in mice. Mol Neurodegener 2013, 8:1.

40. Greenway MJ, Alexander MD, Ennis S, Traynor BJ, Corr B, Frost E, Green A, Da Cruz S, Cleveland DW. The multiple roles of TDP-43 in pre-mRNA processing.

41. Qiu L, Qiao T, Beers M, Tan W, Wang H, Yang B, Xu Z. Widespread aggregation of mutant VAPB associated with ALS does not cause motor neuron degeneration or modulate mutant SOD1 aggregation and toxicity in mice. Mol Neurodegener 2013, 8:1.

42. Greenway MJ, Alexander MD, Ennis S, Traynor BJ, Corr B, Frost E, Green A, Da Cruz S, Cleveland DW. The multiple roles of TDP-43 in pre-mRNA processing.

43. Qiu L, Qiao T, Beers M, Tan W, Wang H, Yang B, Xu Z. Widespread aggregation of mutant VAPB associated with ALS does not cause motor neuron degeneration or modulate mutant SOD1 aggregation and toxicity in mice. Mol Neurodegener 2013, 8:1.

44. Padhi AK, Kumar H, Vasaikar SV, Jayaram B, Gomes J. Assignment of ubiquilin2 (UBQLN2) to human chromosome xp11: 23 – p11.1 by Gene Bridge radiation hybrids. Cytogenet Cell Genet 2000, 89:116–117.

45. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle FE. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Mol Neurodegener 2011, 6:42.

46. Luty AA, Kwok JB, Dobson-Stone C, Loy CT, Coupland KG, Karlström H, Luty AA, Kwok JB, Dobson-Stone C, Loy CT, Coupland KG, Karlström H. Loss of TDP-43.

47. How do C9ORF72 hexanucleotide repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia? Can we learn from other noncoding repeat expansion disorders? Curr Neurol Neurosurg Pract 2012, 12(suppl 2):S22–S26.

48. Kaye FJ, Shows TB. Assignment of ubiquilin2 (UBQLN2) to human chromosome xp11: 23 – p11.1 by Gene Bridge radiation hybrids. Cytogenet Cell Genet 2000, 89:116–117.

49. Luty AA, Kwok JB, Dobson-Stone C, Loy CT, Coupland KG, Karlström H, Luty AA, Kwok JB, Dobson-Stone C, Loy CT, Coupland KG, Karlström H. Loss of TDP-43.

50. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle FE, de Belleruche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668–1672.

51. Luty AA, Kwok JB, Dobson-Stone C, Loy CT, Coupland KG, Karlström H, Luty AA, Kwok JB, Dobson-Stone C, Loy CT, Coupland KG, Karlström H. Loss of TDP-43.

52. Da Cruz S, Cleveland DW. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr Opin Neurol Biol 2011, 24:904–919.

53. Buratti E, Baralle FE. Mamm Genome 2007, 22:448–450.

54. Luty AA, Kwok JB, Dobson-Stone C, Loy CT, Coupland KG, Karlström H, Luty AA, Kwok JB, Dobson-Stone C, Loy CT, Coupland KG, Karlström H. Loss of TDP-43.

55. Michelli RH, Dowke SK. A protein complex that regulates PtdIns(3,5)P2 levels. EMBO J 2009, 28:866–97.

56. Zhang Y, Zolov SN, Chow CY, Slutsky SG, Richardson SC, Piper RC, Yang B, Nau JJ, Westrick RJ, Morrison SJ, Meisler MH, Weismann LS. Loss of Vac14, a regulator of the signaling lipid phosphatidylinositol 3,5-biphosphate, results in neurodegeneration in mice. Proc Natl Acad Sci USA 2007, 104:17156–17163.

57. Fukuda T, Tsumoto T, Yoshida A, Maruyama H, Kowashima H, Opheim C. Optineurin with amyotrophic lateral sclerosis-related mutations abrogates inhibition of interferon regulatory factor-3 activation. Neurosci Lett 2011, 505:279–281.

58. Wild P, Farhan H, McEwan DG, Wagner S, Rogov W, Brady NR, Richter B, Korac J, Waidmann O, Chough CY, Dötsch V, Bumann D, Dikic I. Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. Science 2011, 333:228–233.

59. Korac J, Schaeffer V, Kovacevic I, Clement AM, Jungblut B, Behl C, Terzic J, Dikic I. Ubiquitin-independent function of optineurin in autophagic clearance of aggregate proteins. J Cell Sci 2013, 126:580–592.

60. Johnson JD, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gornick S, Wu, Ding J, McCluskey L, Martinez-Lage M, Falcone D, Hernandez DG, Arepalli S, Chong S, Schymick JC, Rothstein J, Landi F, Wang YD, Calvo A, Mota S, Gass M, Sabatelli M, Monsuur MR, Battistini S, Salvi F, Spataro R, Vella A, Borchgorto G, Consortium ITALSGEN, Galassi G, Scholz SW, Taylor JP, Restagno G, Chib A, Traynor BI. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neurosci Lett 2010, 468:587–884.

61. Lee SM, Garcia-Fuentes J, Miller SE, Watts G, Smith C, Forman M, Hanson PJ, Kumoris V, Petronini A. TDP-43 accumulation in inclusion body muscle myopathy suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2009, 78:1186–1189.

62. Ishikawa H, Yanai K, Oketa Y, Suzuki M, Ono S. Increased expression of valosin-containing protein in the skin of patients with amyotrophic lateral sclerosis. J Clin Neurol 2012, 15:522–526.

63. Kaye FJ, Shows TB. Assignment of ubiquilin2 (UBQLN2) to human chromosome xp11: 23 – p11.1 by Gene Bridge radiation hybrids. Cytogenet Cell Genet 2000, 89:116–117.

64. Deng HX, Chen H, Wang H, Sotow MA, Bigio EH, Chong S, Schymick JC, Corr B, Frost E, Green A, Da Cruz S, Cleveland DW. The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol 2010, 7:420–429.

65. Polymenidou M, Lagier-Tourenne C, Hutt R, Huelga SC, Moran J, Liang TY, Ling SC, Kuklewicz E, Mazur C, Kordasiewicz H, Sedaghat Y, Donohue JP, Shue L, Bennett CY, Yue GW, Cleveland DW. Long pre-mRNA processing and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 2011, 14:459–468.

66. Tollervey JR, Cuck T, Rogelj B, Briese M, Cereda M, Kaykoi M, König J, Hortobágyi T, Nishimura AL, Zupunski V, Patani R, Chandran S, Rot G, Zupan B, Shaw CE, Ule J. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci 2011, 14:452–458.

67. Higashi S, Tsuchiya Y, Araki T, Wada K, Kabata T. TDP-43 physically interacts with amyotrophic lateral sclerosis-linked mutant CuZn superoxide dismutase. Neurochem Int 2010, 57:506–913.

68. Tsaio W, Jeong YH, Lin S, Jing J, Price DL, Chiang PM, Wong PC. Rodent models of TDP-43: recent advances. Brain Res Rev 2012, 1462:39.

69. Gendron TF, Petrucelli L. Rodent models of TDP-43 proteinopathy: investigating the mechanisms of TDP-43-mediated neurodegeneration. J Mol Neurosci 2011, 45:486–499.

70. Xu ZS. Does a loss of TDP-43 function cause neurodegeneration? Mol Neurodegener 2012, 7:27.

71. Joyce PI, Fratta P, Fisher EM, Acevedo-Arozena A. SOD1 and TDP-43. An animal model of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm Genome 2011, 22:440–448.

72. Chow CY, Zhang Y, Dowling JJ, Jin N, Adamska M, Shiga K, Szegi K, Shy ME, Li J, Zhang X, Lupski JR, Weisman LS, Meisler MH. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 2007, 448:58–72.
73. Rademakers R, Neumann M, Mackenzie IR: Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurosci 2012, 12:423–443.

74. Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kiemmer E, Schmid B, Kretzschmar HA, Cuts M, Van Broeckhoven C, Haass C, Edbauer D: The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTD/ALS. Science 2013, 339:1335–1336.

75. Ash PE, Bensiek KD, Gendron TF, Lin WL, Dejesus-Hernandez M, van Blitterswijk MM, Jensen-West K, Paul JW 3rd, Rademakers R, Boylan KB, Dickson DW, Petrucci L: Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Nature 2013, 773:89–946.

76. Polymenidou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW, Yeo GW: Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res 2012, 1426:135–.

77. Münch C, Friede M, Meyer T, Homburg V, Sperfeld AD, Kurt A, Prudic J, Perolla G, Hanemann CO, Stumm G, Ludolph AC: Point mutations of the p50 subunit of dynactin (DCTN1) gene encoding p150(glued) to human chromosome 2p13 by fluorescence in situ hybridization. Genomics 1996, 31:398–399.

78. Lai C, Lin X, Chandran J, Shim H, Yang WJ, Cai H, Holzbaur ELF, Tokito MK: Localization of the DCTN1 gene encoding p150(glued) causes dysfunction of dynactin in mice. J Neuroscience 2007, 27:19382–13990.

79. Laird FM, Farhat MH, Ackerley S, Hoke A, Maragakis N, Rothstein JD, Grifin J, Price DL, Martin LJ, Wong PC: Motor neuron disease occurring in a mutant dynactin mouse model is characterized by defects in vesicular trafficking. J Neuroscience 2008, 28:1997–2005.

80. Puls I, Jonnakuti C, LAMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Shim H, Yang WJ, Cai H, Holzbaur ELF, Tokito MK: DCTN1 gene associated with a mutation in D-amino acid oxidase. J Neurogenetics 2010, 23:514–556.

81. Mitchell J, Paul P, Chen HJ, Morris A, Payling M, Falchi M, Habgood J, Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Shim H, Yang WJ, Cai H, Holzbaur ELF, Tokito MK: DCTN1 gene encoding p150(glued) causes dysfunction of dynactin in mice. J Neuroscience 2007, 27:19382–13990.

82. Münch C, Friede M, Meyer T, Homburg V, Sperfeld AD, Kurt A, Prudic J, Perolla G, Hanemann CO, Stumm G, Ludolph AC: Point mutations of the p50 subunit of dynactin (DCTN1) gene encoding p150(glued) to human chromosome 2p13 by fluorescence in situ hybridization. Genomics 1996, 31:398–399.
112. Brockington A: Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2006, 65:26–36.

113. Lambrechts D, Poesen K, Fernández-Santiago R, Al-Chalabi A, Del Bo R, Van Vught PW, Khan S, Marklund SL, Brockington A, van Marion I, Anneser J, Shaw C, Ludolph AC, Leigh NP, Comi GP, Gasser T, Shaw PJ, Morrison KE, Andersen PM, Van den Berg LH, Thijs V, Siddique T, Robberecht W, Carmeliet P: Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. J Med Genet 2009, 46:840–846.

114. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Mekuist S, Richardson A, Dickson D, Berger Z, Erikson J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M: Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006, 442:916–919.

115. Schymick JC, Yang Y, Andersen PM, Vonsattel JP, Greenway M, Momeni P, Elder J, Chib A, Restagno G, Robberecht W, Dahlberg C, Mukherjee O, Gaite A, Graff-Radford N, Cassell RJ, Hutton M, Gass J, Canon A, Rademakers R, Singleton AB, Hardman O, Rothstein J, Hardy J, Taynor BJ: Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. J Neural Neurosurg Psychiatry 2007, 78:754–756.

116. Elden AC, Kim HI, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armaoka M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, Rub U, Auburger G, Trojanowski JQ, Lee VM, Van Deerlin VM, Bonini NM, Gitter AD: Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010, 466:1069–1075.

117. Kaiser M, Nonhoff U, Albrecht M, Lengauer T, Wanker EE, Lehrach H, Krobitch S: Ataxin-2 and huntingtin interact with endophilin-A complexes to function in plastin-associated pathways. Hum Molec Genet 2005, 14:2893–2909.